Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 59,025 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This trade represents a 7.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Medpace Stock Performance

NASDAQ MEDP traded down $5.21 during trading on Wednesday, hitting $606.60. 305,238 shares of the company’s stock traded hands, compared to its average volume of 412,083. The stock has a market capitalization of $17.09 billion, a price-to-earnings ratio of 42.42, a PEG ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26. The business has a 50 day moving average of $554.32 and a 200-day moving average of $439.13.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analysts’ expectations of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace’s revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Private Advisor Group LLC boosted its stake in shares of Medpace by 12.3% in the 1st quarter. Private Advisor Group LLC now owns 2,502 shares of the company’s stock valued at $762,000 after purchasing an additional 275 shares in the last quarter. Assetmark Inc. grew its stake in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after buying an additional 43 shares during the last quarter. HB Wealth Management LLC purchased a new position in shares of Medpace in the first quarter worth about $256,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Medpace by 4.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,046 shares of the company’s stock valued at $2,147,000 after acquiring an additional 326 shares during the last quarter. Finally, LPL Financial LLC boosted its holdings in Medpace by 2.3% during the 1st quarter. LPL Financial LLC now owns 18,374 shares of the company’s stock valued at $5,469,000 after acquiring an additional 414 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on MEDP. Jefferies Financial Group raised their target price on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a research note on Tuesday, September 9th. Truist Financial set a $555.00 target price on shares of Medpace in a research note on Monday, October 27th. Barclays boosted their price target on shares of Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research report on Friday, October 24th. Cowen reiterated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Finally, Mizuho upped their target price on Medpace from $575.00 to $655.00 and gave the stock an “outperform” rating in a research note on Friday, October 24th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $487.18.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.